An open, non comparative study of ofloxacin i.v. on the treatment of acute symptomatic urinary tract infection.
The clinical efficacy and the safety of ofloxacin i.v. in 35 acute symptomatic urinary tract patients were evaluated. The drug was intravenously administered, 400 mg starting dose then 200 mg once-daily for 3-5 days. The therapeutic success rate and eradication rate in UTI case were 100 per cent in all cases when evaluated immediately after completion of drug treatment, therapeutic success rate and eradication rate at the follow-up evaluation were 97.2 per cent and 91.6 per cent respectively. Also, 5 cases of acute bronchitis and 2 salmonellosis were also administered intravenously, 400 mg once-daily dose and 400 mg twice daily dose respectively. No serious side effects of ofloxacin i.v. therapy were observed in any of our patients.
Department of Family Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
K
K
Asvanich
V
V
Fugpholngam
S
S
Srimuang
D
D
Tanphaichitra
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D011379:Prognosis; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000175:diagnosis / Q000188:drug therapy*
D015242:Ofloxacin